Current clinical issues impacting the lives of patients living with HIV/AIDS

Area of Science:

• Infectious Diseases
• Endocrinology
• Cardiology

Background:

• Highly active antiretroviral therapy (HAART) has transformed HIV type 1 infection management, significantly reducing mortality and morbidity.
• Lifelong HAART is essential for therapeutic benefits but is associated with increased risks of metabolic comorbidities, including dyslipidemia, hyperglycemia, and lipodystrophy.
• These metabolic complications, such as type 2 diabetes mellitus and cardiovascular disease, pose significant challenges for patients on HAART.

Purpose of the Study:

• To review the differential metabolic effects of various HAART regimens.
• To discuss the clinical implications of these metabolic comorbidities in patients living with HIV/AIDS.
• To explore strategies for managing metabolic complications without compromising HAART adherence.

Main Methods:

• Review of current literature on HAART regimens and their associated metabolic side effects.
• Analysis of clinical data regarding the incidence and progression of dyslipidemia, hyperglycemia, and lipodystrophy in HIV-infected patients.
• Evaluation of current pharmacotherapeutic interventions for metabolic comorbidities in the context of HAART.

Main Results:

• Different HAART regimens exhibit varying propensities to induce metabolic disturbances.
• Hyperlipidemia and hyperglycemia are common, potentially leading to lipodystrophy and type 2 diabetes mellitus.
• Patients on HAART with metabolic comorbidities face an elevated risk of cardiovascular disease.

Conclusions:

• Metabolic comorbidities are a significant concern for patients on HAART, impacting long-term health outcomes.
• Understanding the differential metabolic effects of HAART regimens is critical for personalized patient management.
• Effective management strategies are needed to address metabolic complications and improve adherence to lifelong HIV therapy.